Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
SeethalerBBasraiMNeyrinckAMNazareJAWalterJDelzenneNMet al
Competing interests The authors declare no competing interests
In cellular assays, the number n = 3 or 6 indicated that all experiments were replicated for three or six times independently
Theres a lot of anecdotes on social media about supplements that give hope to people in the same situation
Ipamorelin + CJC-1295 Stack: Evidence, Mechanism, and Protocol At a glance Drug class / Growth hormone secretagogue (GHRP) + Growth hormone-releasing hormone analogue (GHRH analogue) Ipamorelin receptor target / Ghrelin receptor (GHSR-1a), selective, no cortisol or prolactin spike CJC-1295 receptor target / GHRH receptor (GHRHR) on pituitary somatotrophs Combination mechanism / GHRP + GHRH co-stimulation raises GH pulse amplitude 2-to-10-fold over either agent alone in animal models Typical ipamorelin dose / 100-300 mcg subcutaneous injection, 1-3x daily Typical CJC-1295 (no DAC) dose / 100-300 mcg subcutaneous injection, timed with ipamorelin Typical CJC-1295 with DAC dose / 1,000-2,000 mcg subcutaneous injection, once weekly Primary evidence level / Mechanistic + animal + one Phase II RCT (CJC-1295)
Recent research has focused more on the investigation of new nutritional interventions in the context of nursing care and rehabilitation for people with T2DM
